Allogene Therapeutics Inc (ALLO)
Healthcare
Biotechnology
1.80 $
-2.1%
vs. previous close
Closing price · As of: 3. Aug 2026
Allogene Therapeutics Inc (ALLO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -13 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -62 | -56 | -54 | -56 | -64 | -44 | -37 | -53 | -39 | -30 | -28 | -13 | -109 | |
| 3.6 | 3.6 | 3.5 | 3.6 | 3.6 | 3.2 | 3.2 | 3.1 | 3.1 | 3.1 | 3.1 | 2.9 | 12 | |
| 17 | 15 | 15 | 12 | 14 | 13 | 13 | 12 | 8.7 | 8.7 | 8.1 | 8.3 | 34 | |
| 17 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -4.4 | -15 | -3.4 | -4.4 | -17 | 21 | 5.3 | -8.3 | -2.2 | -0.1 | -0.2 | 18 | 16 | |
| 0.3 | 0.0 | 0.2 | 0.0 | 0.0 | 0.4 | 0.3 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.3 | |
| 17 | -34 | 67 | 22 | 75 | -76 | 55 | 6.2 | 44 | 12 | 34 | -30 | 60 | |
| 90 | – | 2.5 | 0.9 | – | 0.7 | – | 0.6 | – | 0.3 | – | 0.5 | – | |
| 90 | 4.3 | 0.2 | 1.7 | 109 | 0.7 | 5.7 | 14 | 5.1 | 3.2 | 7.9 | 21 | 37 | |
| 45 | -86 | 14 | -32 | 120 | -119 | 24 | -33 | 9.9 | -15 | 14 | -21 | -12 | |
| -62 | -56 | -54 | -56 | -64 | -45 | -37 | -53 | -39 | -30 | -28 | -13 | -110 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.